Prostate Cancer Home > Firmagon and Breastfeeding
Firmagon (degarelix) is not recommended for use in women who are nursing, as it is unknown whether the medicine passes through breast milk or if it would harm a nursing infant. Although this medication is only approved for use in men with prostate cancer, women may receive this medicine for unapproved reasons. However, the manufacturer of the drug recommends that breastfeeding women avoid Firmagon.
Can Breastfeeding Women Use Firmagon?Firmagon® (degarelix) is a prescription prostate cancer medication. Specifically, Firmagon is approved for use in men with advanced prostate cancer, which means the cancer has spread beyond the prostate to other parts of the body.
At this time, it is unknown if Firmagon passes through breast milk in humans. The manufacturer of the medication recommends that women not use Firmagon while breastfeeding.
More Information on Firmagon and BreastfeedingNo research has been done on breastfeeding and Firmagon. Therefore, it is unknown if the medicine passes through breast milk, if it would harm a nursing infant, or whether it has negative effects on breast milk production.
At this time, Firmagon is only approved for use in men with prostate cancer. So, any Firmagon use in women would be an "off-label," or unapproved, use.
Firmagon works by decreasing testosterone and estrogen levels. Because of the potential risks for side effects in a nursing infant, Firmagon should probably be avoided in women who wish to breastfeed their child.